Press Releases

Date	Title and Summary	Additional Formats
Toggle SummaryJun052014	Fate Therapeutics to Highlight Potential Clinical Applications of Ex Vivo Hematopoietic Cell Modulation at 12th International Cord Blood Symposium SAN DIEGO, June 5, 2014 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, today announced that potential clinical applications of its ex vivo approach to Read All »	View HTML Fate Therapeutics to Highlight Potential Clinical Applications of Ex Vivo Hematopoietic Cell Modulation at 12th International Cord Blood Symposium 16.7 KB
Toggle SummaryMay282014	Fate Therapeutics to Present at Jefferies 2014 Global Healthcare Conference SAN DIEGO, May 28, 2014 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, announced today that Christian Weyer, M.D., M.A.S., President and Chief Executive Officer, Read All »	View HTML Fate Therapeutics to Present at Jefferies 2014 Global Healthcare Conference 10.1 KB
Toggle SummaryMay132014	Fate Therapeutics Reports First Quarter 2014 Financial Results Phase 2 PUMA Study of PROHEMA® in Adult Hematologic Malignancies Enrolling Patients Phase 1b PROMPT Study of PROHEMA in Pediatric Hematologic Malignancies Cleared by FDA IND Submission for Study of PROHEMA in Rare Genetic Disorders Expected in 2Q14 SAN DIEGO, May 13, 2014 (GLOBE NEWSWIRE) -- Read All »	View HTML Fate Therapeutics Reports First Quarter 2014 Financial Results 25.2 KB
Toggle SummaryMay062014	Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2014 Financial Results on May 13, 2014 SAN DIEGO, May 6, 2014 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, today announced that the Company will host a conference call and live audio webcast on Read All »	View HTML Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2014 Financial Results on May 13, 2014 10.4 KB
Toggle SummaryApr302014	Fate Therapeutics to Present at Deutsche Bank 39th Annual Health Care Conference SAN DIEGO, April 30, 2014 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, announced today that Christian Weyer, M.D., M.A.S., President and Chief Executive Read All »	View HTML Fate Therapeutics to Present at Deutsche Bank 39th Annual Health Care Conference 10.3 KB
Toggle SummaryApr232014	Fate Therapeutics Announces FDA Clearance of IND Amendment for Clinical Development of PROHEMA(R) in Pediatric Patients Phase 1b PROMPT Study in Hematologic Malignancies Expected to Begin in Mid-2014 Read All »	View HTML Fate Therapeutics Announces FDA Clearance of IND Amendment for Clinical Development of PROHEMA(R) in Pediatric Patients 16.9 KB
Toggle SummaryApr102014	Fate Therapeutics Secures U.S. Patent for Class of Small Molecule Modulators Key to the Development of iPSC-Based Therapeutics SAN DIEGO, April 10, 2014 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, announced today that the U.S. Patent and Trademark Office (PTO) has issued Patent No. Read All »	View HTML Fate Therapeutics Secures U.S. Patent for Class of Small Molecule Modulators Key to the Development of iPSC-Based Therapeutics 14.6 KB
Toggle SummaryMar172014	Fate Therapeutics Appoints Dr. Robert S. Epstein to Its Board of Directors SAN DIEGO, March 17, 2014 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, announced today that Dr. Robert S. Epstein, M.D., has joined its Board of Directors. Dr. Read All »	View HTML Fate Therapeutics Appoints Dr. Robert S. Epstein to Its Board of Directors 84.4 KB
Toggle SummaryMar172014	Fate Therapeutics Reports Fourth Quarter and Full Year 2013 Financial Results Phase 2 PUMA Study of PROHEMA® Initiated - Interim Data Expected in 2H14 Clinical Trial of PROHEMA ® in Lysosomal Storage Disorders to Begin in 2H14 Encouraging Clinical Data Published Highlighting the Potential of Ex Vivo T Cell Modulation SAN DIEGO, March 17, 2014 (GLOBE NEWSWIRE) -- Read All »	View HTML Fate Therapeutics Reports Fourth Quarter and Full Year 2013 Financial Results 84.4 KB
Toggle SummaryMar122014	Fate Therapeutics Commences Phase 2 Clinical Trial of PROHEMA(R) for the Treatment of Hematologic Malignancies First Patient Enrolled in PUMA Study Approved for Conduct at Ten Leading U.S. Centers Interim Data Expected in 2H14 SAN DIEGO, March 12, 2014 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators Read All »	View HTML Fate Therapeutics Commences Phase 2 Clinical Trial of PROHEMA(R) for the Treatment of Hematologic Malignancies 18.6 KB

DISCLOSURE NOTICE: The information contained in each press release is as of the date of the respective press release. The Company assumes no obligation to update any information or forward-looking statement contained in any press release as a result of new information or events or developments arising after the date of such press release.